Study S002767

A PhaseⅢ Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07648225
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 600
Start: 2026-07-31
Primary completion: 2027-09-29
Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Obesity & Overweight
Interventions: DRUG:UBT251 Injection 4.0 mg; DRUG:UBT251 Injection 6.0 mg; DRUG:UBT251 Injection Placebo 4.0 mg; DRUG:UBT251 Injection Placebo 6.0 mg
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Body Weight [Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.